share_log

DaVita | 10-Q: Q3 2024 Earnings Report

DaVita | 10-Q: Q3 2024 Earnings Report

德維特 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/30 05:09

Moomoo AI 已提取核心訊息

DaVita reported Q3 2024 consolidated revenues of $3.26 billion, up 2.4% from Q2 2024, with operating income increasing 5.7% to $535 million. U.S. dialysis revenue grew 2.3% to $2.91 billion, driven by increased average reimbursement rates and treatment volumes. Patient service revenue per treatment rose to $394.49, up 1.1% from Q2.The company's international operations expanded significantly, with revenues increasing 6.6% quarter-over-quarter to $258 million. Operating expenses increased, with patient care costs rising 2.0% to $1.89 billion due to higher compensation expenses and wage rates. The company completed $406 million in share repurchases during the quarter, acquiring 2.73 million shares.Looking ahead, DaVita faces ongoing challenges from labor market pressures and supply chain disruptions, particularly following Hurricane Helene's impact on Baxter's manufacturing facility. The company has implemented operational changes including conservation measures and temporary holds on new peritoneal dialysis starts. As of September 30, 2024, DaVita operated 2,660 U.S. dialysis centers and 453 international centers.
DaVita reported Q3 2024 consolidated revenues of $3.26 billion, up 2.4% from Q2 2024, with operating income increasing 5.7% to $535 million. U.S. dialysis revenue grew 2.3% to $2.91 billion, driven by increased average reimbursement rates and treatment volumes. Patient service revenue per treatment rose to $394.49, up 1.1% from Q2.The company's international operations expanded significantly, with revenues increasing 6.6% quarter-over-quarter to $258 million. Operating expenses increased, with patient care costs rising 2.0% to $1.89 billion due to higher compensation expenses and wage rates. The company completed $406 million in share repurchases during the quarter, acquiring 2.73 million shares.Looking ahead, DaVita faces ongoing challenges from labor market pressures and supply chain disruptions, particularly following Hurricane Helene's impact on Baxter's manufacturing facility. The company has implemented operational changes including conservation measures and temporary holds on new peritoneal dialysis starts. As of September 30, 2024, DaVita operated 2,660 U.S. dialysis centers and 453 international centers.
德維特報告稱2024年第三季度綜合營業收入爲32.6億，同比增長2.4%，營業收入增長5.7%，達到53500萬。美國透析營業收入增長2.3%，達到29.1億，這得益於平均報銷率和治療量的增加。每次治療的患者服務營收提高至394.49美元，比第二季度增長1.1%。該公司的國際業務顯著擴張，季度收入環比增長6.6%，達到25800萬。營業費用增加，患者護理成本上升2.0%，達到18.9億，主要由於更高的薪酬費用和工資水平。該公司在本季度回購了40600萬的股份，購回273萬股。展望未來，德維特面臨來自勞動力市場壓力和供應鏈中斷的持續挑戰，尤其是在颶風海倫對百特製造設施造成影響之後。公司已實施包括節能措施和對新腹膜透析開始暫時擱置等運營變更。截至2024年9月30日，德維特在美國經營2660個透析中心和453個國際中心。
德維特報告稱2024年第三季度綜合營業收入爲32.6億，同比增長2.4%，營業收入增長5.7%，達到53500萬。美國透析營業收入增長2.3%，達到29.1億，這得益於平均報銷率和治療量的增加。每次治療的患者服務營收提高至394.49美元，比第二季度增長1.1%。該公司的國際業務顯著擴張，季度收入環比增長6.6%，達到25800萬。營業費用增加，患者護理成本上升2.0%，達到18.9億，主要由於更高的薪酬費用和工資水平。該公司在本季度回購了40600萬的股份，購回273萬股。展望未來，德維特面臨來自勞動力市場壓力和供應鏈中斷的持續挑戰，尤其是在颶風海倫對百特製造設施造成影響之後。公司已實施包括節能措施和對新腹膜透析開始暫時擱置等運營變更。截至2024年9月30日，德維特在美國經營2660個透析中心和453個國際中心。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Basel Medical
    BMGL
    -- 4.555
    布魯克代爾高級護理
    BKD
    -- 6.150
    The Oncology Institute
    TOI
    -- 1.1400
    費森尤斯醫療
    FMS
    -- 24.780
    Ardent健康夥伴
    ARDT
    -- 13.200
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日